Your browser doesn't support javascript.
loading
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.
Ferrarotto, Renata; Sousa, Luana G; Qing, Yun; Kaya, Diana; Stephen, Bettzy; Jain, Dipti; Bell, Diana; Pant, Shubham; Tsimberidou, Apostolia M; Janku, Filip; Blumenschein, George; Glisson, Bonnie S; Ahnert, Jordi Rodon; Piha-Paul, Sarina A; Lee, J Jack; Wong, Michael K; Lu, Charles; Meric-Bernstam, Funda; Naing, Aung.
Affiliation
  • Ferrarotto R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rferrarotto@mdanderson.org.
  • Sousa LG; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Qing Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kaya D; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jain D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bell D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Blumenschein G; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Glisson BS; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ahnert JR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wong MK; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lu C; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adv Ther ; 38(8): 4581-4591, 2021 08.
Article in En | MEDLINE | ID: mdl-34241781
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Carcinoma, Squamous Cell / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2021 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Carcinoma, Squamous Cell / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2021 Type: Article Affiliation country: United States